What C4 Therapeutics, Inc. does.

We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transform patients’ lives. Leveraging our proprietary TORPEDO platform, we efficiently design and optimize small molecule protein degraders that are highly active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Our strategy is to develop degraders that modulate clinically validated disease pathways with best-in-class or first-in-class potential to address significant unmet patient needs. To date, our degraders have demonstrated oral bioavailability and catalytic activity, and we have also leveraged our capability to design compounds that are brain penetrant.

Our clinical pipeline has two oncology degraders, cemsidomide, an IKZF1 and IKZF3 degrader, for multiple myeloma, or MM, and CFT8919, an EGFR L858R degrader for non-small-cell lung cancer, or NSCLC. Our discovery strategy is focused on selecting targets where we believe TPD offers a compelling mechanistic rationale and first-in-class potential in inflammation, neuroinflammation and neurodegeneration diseases. Our solely-owned pipeline is reflected below.

Revenue and profit, by fiscal year.

More on CCCC.

• C4 Therapeutics, Inc. summary
• C4 Therapeutics, Inc. financial statements
• C4 Therapeutics, Inc. key metrics
• C4 Therapeutics, Inc. health scores and style box
• C4 Therapeutics, Inc. earnings
• C4 Therapeutics, Inc. dividends
• C4 Therapeutics, Inc. valuation
• C4 Therapeutics, Inc. ownership and insiders
• C4 Therapeutics, Inc. peers

Figures from C4 Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.